KR — The Kroger Co.

Sentiment is stuck between two facts. The bear case is visible in the tape: -22.63% over six months, -9.61% over three months, price sitting 8.42% below its 200-day moving average and only ~8% off a 52-week low. The bull case is the Sept 11, 2026 print: Q2 FY26 sales of $34.62B (+2% YoY), operating income +12% to $971M, adjusted EPS of $1.09 beating ~$1.05 consensus, e-commerce sales +20%, retail media profit +24%, and roughly $1B of stock bought back in the quarter. Investors are also digesting a guidance trim (identical sales ex-fuel cut to 0.2-0.8%), a ~140bp pharmacy sales drag from IRA reimbursement changes, soft SNAP/low-income basket trends, and a produce disruption from a cyclospora outbreak. Analyst stance is a consensus Buy/Moderate Buy with targets clustered around $69-71, but recent cuts (Citigroup to $57) show the sell side is split between 'profit resilience' and 'no top line.'

Revenue growth has quietly re-accelerated. Matched-quarter YoY went from +0.1% in the Aug-2025 quarter ($33.94B) to +0.7% (Nov-25), +1.2% (Jan-26), +2.2% (May-26, $46.12B) and +2.0% in the quarter ended 2026-08-15 ($34.62B vs $33.94B). Operating margin is expanding consistently: 2.81% in the latest quarter vs 2.54% a year earlier, and 3.05% vs 2.93% the quarter before — driven by mix (retail media +24% profit, e-commerce +20%) and cost discipline, not volume. Diluted EPS of $1.46 (Q1 FY26) and $1.05 (Q2 FY26) were up ~13% and ~15% YoY, flattered by a shrinking share count. The critical distortion is the quarter ended 2025-11-08, which posted a -$1.54B operating loss and -$2.02 EPS; that single one-off charge is what makes TTM EPS $1.79, TTM operating margin 1.4%, TTM ROIC 4.7% and the 31.3x TTM P/E look dire. The genuine structural negative is on the top line: management just cut identical sales to 0.2-0.8%, so the earnings improvement is margin/mix/buyback driven rather than volume driven — profit resilience without top-line vitality. Note also that the last quarter's free cash flow was only $1M (OCF $1.145B vs capex $1.144B), versus $462M in Q1 FY26 and $1.80B in the Jan-2026 quarter, so cash generation remains lumpy and capex-hungry.

Expensive on trailing numbers, roughly fair on the numbers that matter. As of 2026-09-13 the TTM P/E was 31.28x against a 5-year average of 21.33x — the source of the deterministic model's 'Rich vs. its own history' tag — but that 31.3x is computed on $1.79 of TTM GAAP EPS that contains a -$2.02 quarter. Measured against FY26 adjusted EPS guidance of $5.10-5.30 (midpoint $5.20), the stock trades at ~11.2x; against the analyst next-FY estimate of $5.197, ~11.3x. P/S of 0.24 is essentially at the 5-year average of 0.25. Trailing EV/EBITDA of 10.87x is impairment-distorted; normalized (roughly $7B EBITDA on an EV of about $52B) it is ~7.4x, mid-range for a grocery retailer. PEG of -0.591 is meaningless here because the trailing growth denominator is distorted. Verdict: ~11x forward for a 2.54%-yielding, buyback-heavy defensive grocer with sub-1% comps is fair, not a bargain — the low multiple is a rational discount for a growth problem, not an obvious mispricing.

At $58.49 the market is paying ~11.2x FY26 guidance and effectively assuming the 0.2-0.8% identical-sales guide is the durable run rate, with minimal credit for the retail media, e-commerce automation and cost programmes that are actually expanding profit. The mechanical bull math is real: roughly $1B of buybacks per quarter at ~11x retires about 1.7% of the float per quarter, so even flat net income produces mid-single-digit EPS growth. But the market is also rationally refusing to pay up for a retailer that cannot grow units, and the guidance trim says management sees the same thing. Practical read: if Kroger simply delivers $5.20 and holds the multiple, you get ~2.5% dividend plus mid-single-digit EPS growth; if identical sales go negative, the multiple has room to compress to 9-10x ($47-52) before value buyers get interested. That asymmetry is not favourable enough to underwrite the base case before the Oct 20, 2026 investor update.

As of 2026-09-13, RSI(14) stood at 54.43 — dead neutral, with no oversold washout to buy. The $58.49 price sat 1.71% above the 20-day SMA (~$57.51) and 1.24% above the 50-day SMA (~$57.77), but 8.42% below the 200-day SMA (~$63.87): a short-term basing bounce inside a medium-term downtrend (6-month return -22.63%, 3-month -9.61%, 1-week -0.17%). Price is ~8% above the 52-week low of $54.15 and ~24% below the high of $76.58, with a beta of 0.406. Timing implication: the 200-day at roughly $63.9 is the line in the sand. Either wait for a retest of $54-55 where risk/reward improves materially, or wait for a decisive reclaim of the 200-day to confirm an actual trend change. Buying now means buying mid-range with resistance directly overhead.

• Consumer caution and pressure on government-funded benefits (SNAP and related) are constraining basket sizes, especially for Kroger's low-to-middle-income core customer, capping organic volume across traditional grocery.
• Inflation Reduction Act pharmacy reimbursement changes are a structural, not cyclical, headwind — management quantified roughly a 140bp drag on pharmacy sales this year.
• Rate and refinancing environment matters more than usual here: $15.16B of long-term debt against $201M of cash and a 0.702 current ratio means a levered balance sheet in a higher-for-longer rate world.
• Grocery price competition from Walmart, Costco, Aldi, Amazon and dollar stores keeps gross margin (22.6% TTM) under pressure and forces continuous price investment.
• Defensive-sector rotation cuts both ways: KR's 0.406 beta makes it a haven if macro weakens, but it also structurally underperforms in risk-on rallies, limiting multiple expansion.

• October 20, 2026 Investor Update — the primary near-term catalyst, where management is expected to lay out pricing architecture, cost-reduction pipeline and structural earnings power; a credible long-term algorithm could re-rate the multiple.
• Q3 FY2026 results (expected early December 2026) — first hard evidence on whether the lowered 0.2-0.8% identical-sales guide holds and whether the IRA pharmacy drag is peaking or persisting.
• Continued aggressive repurchases (~$1B in Q2 FY26 alone) at ~11x earnings — mechanically accretive to EPS and a real floor under per-share metrics.
• Scaling of high-margin engines: retail media (Kroger Precision Marketing, +24% profit) and automated e-commerce fulfilment (+20% sales), which are the only visible margin-expansion levers.
• Execution of the new EVP of Store Operations (Walmart veteran Mark Ibbotson, appointed early September 2026) on value/pricing resets, plus progress on regional expansion including the pending Giant Eagle integration phasing into 2027.

• Identical sales growth has been cut to 0.2-0.8% and sits close to zero; if comps turn negative, the entire buyback-plus-margin EPS algorithm loses its foundation.
• Balance sheet: debt/equity of 4.132, current ratio of 0.702, quick ratio of 0.306, long-term debt of $15.16B against just $201M of cash, and stockholders' equity down from $12.9B (Nov 2024) to $5.85B (Aug 2026) — buyback-driven equity erosion raises the risk of negative equity if another impairment lands.
• Free cash flow quality: the latest quarter produced just $1M of FCF on $1.144B of capex, and the trailing four quarters total only ~$2.27B against roughly $900M of dividends plus multi-billion buybacks, meaning shareholder returns are partly balance-sheet funded.
• Return on invested capital of 4.7% is barely at or below cost of capital — Kroger is not obviously compounding intrinsic value despite reporting 'profit resilience.'
• External shocks are recurring: IRA reimbursement changes (~140bp pharmacy drag), cyclospora produce disruption, and share loss to Walmart/Costco/Aldi/Amazon in a price-competitive grocery market.

Not compelling at $58.49. Kroger is a genuinely defensive, low-beta (0.406) business with real profit-side momentum — Q2 FY26 operating income +12% to $971M, adjusted EPS $1.09 vs ~$1.05 consensus, retail media profit +24%, e-commerce sales +20% — but the top line is stalled (identical-sales guidance cut to 0.2-0.8%), ROIC of 4.7% barely clears its cost of capital, and 4.132x debt/equity with a 0.702 current ratio and $201M of cash leaves little room for error while equity has shrunk from $12.9B to $5.85B in under two years. At ~11.2x FY26 adjusted EPS the stock is cheap in absolute terms, but not cheap enough to compensate for a deteriorating comp trajectory and no visible catalyst until the Oct 20, 2026 investor update. I would want either a retest of the $54-55 area or evidence that identical sales can inflect positive before treating this as a buy.

Applied a 12.0x multiple — the midpoint of Kroger's own roughly 11-13x historical forward-EPS range, justified by sub-1% identical sales growth and a 4.7% ROIC — to forward adjusted EPS of $5.20 (midpoint of FY26 guidance of $5.10-5.30), giving $62.40, rounded to $62. Cross-check: ~7.5x normalized EV/EBITDA on roughly $7.0B of EBITDA (normalized operating income near $3.3B plus ~$3.7B D&A) less about $16B of net debt against ~613M shares implies $59-65, bracketing the same level; no terminal growth premium was added because the evidence does not support volume growth.